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Replacement of an abnormal lymphohemato­
poietic system by allogeneic hematopoietic stem 
cell transplantation (aHSCT) from a healthy 
donor is an effective treatment for many dis­
orders of the hematopoietic system (Sykes and 
Nikolic, 2005; Copelan, 2006). Induction of a 
mixed hematopoietic donor­host chimerism 
can induce long­lasting tolerance to foreign tis­
sues without the need for life­long immuno­
suppressive therapy (Kawai et al., 2008). aHSCT 
therapy  has  been  improved  by  better  donor 
identification (Petersdorf et al., 2004), more 
tolerable  conditioning  regimens  (McSweeney 
et al., 2001), and enhanced supportive care. 
However, significant treatment­related morbidity 
and mortality from chemotherapy, radiotherapy, 
infections, and graft­versus­host disease (GVHD) 
remain significant clinical problems. Therefore, 
aHSCT is commonly indicated only for treat­
ment of conditions where other treatment op­
tions are far inferior or lacking.
Costimulatory molecules of the CD28 and 
TNF families regulate GVHD, with inhibitory 
and activating receptors either decreasing or in­
creasing its severity (Tamada et al., 2000; Blazar 
et al., 2003; Xu et al., 2007). B and T lympho­
cyte associated (BTLA) is an inhibitory immu­
noglobulin superfamily receptor, whose ligand 
is the TNF receptor herpesvirus entry mediator 
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Graft-versus-host disease (GVHD) causes significant morbidity and mortality in allogeneic 
hematopoietic stem cell transplantation (aHSCT), preventing its broader application to 
non–life-threatening diseases. We show that a single administration of a nondepleting 
monoclonal antibody specific for the coinhibitory immunoglobulin receptor, B and  
T lymphocyte associated (BTLA), permanently prevented GVHD when administered at the 
time of aHSCT. Once GVHD was established, anti-BTLA treatment was unable to reverse 
disease, suggesting that its mechanism occurs early after aHSCT. Anti-BTLA treatment 
prevented GVHD independently of its ligand, the costimulatory tumor necrosis factor receptor 
herpesvirus entry mediator (HVEM), and required BTLA expression by donor-derived T cells. 
Furthermore, anti-BTLA treatment led to the relative inhibition of CD4+ forkhead box  
P3 (Foxp3) effector T cell (T eff cell) expansion compared with precommitted naturally 
occurring donor-derived CD4+ Foxp3+ regulatory T cell (T reg cell) and allowed for graft-
versus-tumor (GVT) effects as well as robust responses to pathogens. These results suggest 
that BTLA agonism rebalances T cell expansion in lymphopenic hosts after aHSCT, thereby 
preventing GVHD without global immunosuppression. Thus, targeting BTLA with a monoclo-
nal antibody at the initiation of aHSCT therapy might reduce limitations imposed by histo-
compatibility and allow broader application to treatment of non–life-threatening diseases.
© 2010 Albring et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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expressed by recipient mice might regulate GVHD in this 
model, we used BTLA/ CB6F1 hosts as recipients of BTLA/ 
BM and splenocytes (Fig. S1 a). BTLA/ donor cells induced 
similar  GVHD  in  BTLA+/  and  BTLA/  hosts,  which  is   
comparable to GVHD by WT donor cells (Fig. 1 a). Col­
lectively, these data suggest that BTLA does not normally regu­
late GVHD.
Because BTLA generates inhibitory signals and functions 
in autoimmunity (Watanabe et al., 2003), malaria infection 
(Lepenies et al., 2007), and intestinal inflammation (Steinberg 
et al., 2008), we wondered whether harnessing the inhibitory 
effects of BTLA on the immune response by forced engage­
ment would attenuate GVHD. To test this, we compared the 
effects of an agonistic nondepleting anti­BTLA monoclonal 
antibody (Hurchla et al., 2005; Lepenies et al., 2007), 6A6, 
administered at the time of aHSCT (Fig. 1 b) with an iso­
type control antibody, PIP, that recognizes bacterial GST 
(Gronowski et al., 1999). Mice treated with PIP showed sim­
ilar progression of GVHD (Fig. 1, a and b), with clinical 
scores between 3 and 4 persisting for >140 d (Fig. S1 b). 
GVHD was associated with thickening of the lamina propria 
and muscularis, with severe inflammation and ulceration of 
(HVEM) and which has only been examined in a nonirradi­
ated model of chronic allostimulation without classical GVHD 
where donor cells lacking BTLA failed to persist (Hurchla   
et al., 2007). The role of BTLA in aHSCT using irradiated 
recipients, in which clinical symptoms and pathology similar 
to human GVHD develop, has not been examined.
RESULTS AND DISCUSSION
To determine the role of BTLA in the development of 
GVHD, we first examined WT and BTLA/ donor mice 
(Watanabe et al., 2003) using a nonlethal parent­into­irradiated 
F1 model of aHSCT (Stelljes et al., 2008). In this model, 
GVHD results from partial MHC mismatch between H­2b 
haplotype donor cells and lethally irradiated H­2b/d haplotype 
recipients. BM and splenocytes from WT or BTLA/ mice 
on the C57BL/6 background were transferred into lethally 
irradiated CB6F1 recipients (Fig. 1 a). Transplantation of 
WT donor cells into CB6F1 recipients caused body weight 
loss of 30% and clinical scores (Cooke et al., 1996) of 3 
that persisted for >40 d. BTLA/ and WT donor cells 
caused similar GVHD, suggesting that BTLA does not nor­
mally regulate GVHD in this model. To test whether BTLA 
Figure 1.  Anti-BTLA treatment permanently prevents GVHD. (a) Lethally irradiated CB6F1 mice received BMC and splenocytes from C57BL/6 WT 
(closed squares, n = 5) or BTLA/ (open squares, n = 5) donors. (b) Lethally irradiated CB6F1 mice received BMC and splenocytes from syngeneic donors 
(closed squares, n = 10), C57BL/6 mice and antibodies PIP (open circles, n = 15), or 6A6 (closed circles, n = 15). Shown are cumulative data from three 
independent experiments. (c) Lethally irradiated CB6F1 mice received BMC and splenocytes from C57BL/6 mice plus control antibody PIP (open circles,  
n = 5) or 6A6 (closed circles, n = 5) on the day of BMT or 6A6 14 d after BMT (open squares, n = 5). (d) Lethally irradiated CB6F1 mice received BMC and 
splenocytes from C57BL/6 HVEM/ mice and control antibody PIP (open circles, n = 5) or 6A6 (closed circles, n = 5). (e) Lethally irradiated BALB/c mice 
received TCD-BM alone (green lines and closed squares, n = 10) or in combination with splenocytes from C57BL/6 mice and control antibody PIP (red lines 
and open circles, n = 10) or 6A6 (blue lines and closed circles, n = 10) on the day of BMT. Shown are cumulative data from two independent experiments. 
Weight and clinical score data shown are mean ± SD. Data are representative of two independent experiments with five mice per group or cumulative 
data from independent experiments as indicated. P-values of >0.05 are considered not significant (n.s). ***, P < 0.001.JEM VOL. 207, November 22, 2010  2553
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within 30 d after aHSCT from severe GVHD (Fig. 1 e, right). 
Although mice that received the anti­BTLA treatment were 
not fully protected from GVHD, with clinical scores ranging 
from 1 to 3 (Fig. 1 e, middle) and slightly more weight loss than 
the control group that had received T cell–depleted BM cells 
(BMCs [TCD­BMs]) alone (Fig. 1 e, left), 70% of recipients 
treated with 6A6 survived for >200 d after aHSCT.
Although the precise molecular targets of BTLA signaling 
are  still  obscure  (Gavrieli  and  Murphy,  2006;  Wu  et  al., 
2007), BTLA engagement by HVEM can inhibit T cell pro­
liferation in vitro (Sedy et al., 2005) and promote tolerance 
induction in vivo (Liu et al., 2009). Therefore, we asked if 
anti­BTLA treatment alters donor T cell proliferation or IL­2 
production in vivo. CFSE­labeled donor splenocytes were 
transferred into CB6F1 recipients that were treated with PIP, 
6A6, or 6F7. Donor T cell proliferation was assessed after 
aHSCT and, by 3 d after aHSCT, reduced CFSE levels sug­
gested  that  proliferation  had  occurred  (Fig.  2  e).  CD4+  
T cells had reduced proliferation after treatment with 6A6   
and 6F7 antibodies 3 d after aHSCT (Fig. 2 e, middle), and the 
total accumulation of donor CD4+ T cells was significantly 
reduced compared with control (P < 0.0018 and P < 0.0083; 
Fig. 2 b). In contrast, CD8+ T cell proliferation and accu­
mulation were not significantly affected by 6A6 treatment   
(P < 0.8489; Fig. 2, a and e, left). As 6F7 treatment leads to 
partial depletion of cells, we also assessed the level of annexin   
V binding, which is an indicator of early apoptosis. Mice 
treated with 6F7, but not PIP or 6A6, showed increased bind­
ing of annexin V on CD4+ and CD8+ T cells 7 d after aHSCT, 
which was not observed on day 3 (Fig. S1 g).
Although accumulation of CD4+ T cells was lower in 6A6­ 
treated than in PIP­treated mice, the production of IL­2 7 d 
after aHSCT was not statistically different (Fig. S2, a and b). 
A small but significant reduction in IFN­ and IL­4, but not 
IL­17, production was observed in 6A6­treated mice com­
pared with controls (Fig. S2, a and b). In summary, 6A6 ad­
ministered at the time of aHSCT reduced the proliferation 
and accumulation of donor­derived CD4+Foxp3 effector   
T cells (T eff cells) without inducing anergy, inhibiting IL­2 
production or causing major alterations in cytokines.
These  effects  were  suggestive  of  the  actions  of  CD4+ 
Foxp3+ regulatory T cells (T reg cells) expressing the tran­
scription factor forkhead box P3 (Foxp3; Hori et al., 2003). 
T reg cells have recently been reported to play a significant 
role in regulating GVHD (Taylor et al., 2002; Edinger et al., 
2003b), and there are ongoing clinical trials aimed directly at 
the use of T reg cells as an intervention in human GVHD 
(NCI clinical trial NCT00725062).
To determine whether 6A6 treatment influences T reg 
cells, we measured the accumulation and proliferation of   
donor­derived T eff cells after aHSCT (Fig. 2, c and e, right). 
In PIP­treated recipients that developed GVHD, significantly 
fewer T reg cell were detected 7 d (P < 0.0393) after aHSCT 
when compared with recipients that received either anti­
BTLA treatment 6A6 or 6F7 (Fig. 2 c). Therefore, anti­
BTLA treatment inhibits the proliferation of T eff cells yet 
the colon (Stelljes et al., 2008; Fig. S1 c, bottom). In contrast, 
a single treatment of 10 µg/g body weight of 6A6, given at 
the time of aHSCT, prevented GVHD completely, with weight 
loss and GVHD similar to the syngeneic control group (Fig. 1 b) 
for 140 d after aHSCT (Fig. S1 b). Furthermore, 6A6­treated 
mice had no histological evidence of GVHD in the colon 
(Fig. S1 c, top). Thus, a single administration of anti­BTLA 
antibody  eliminates  weight  loss,  histological  changes,  and 
clinical signs of GVHD.
We next asked if 6A6 acted by simply depleting donor cells 
that express BTLA. As a positive control, we included a de­
pleting murine anti­BTLA antibody, 6F7 (Hurchla et al., 2005; 
Truong et al., 2009). CFSE­labeled donor cells were trans­
ferred into WT recipients that also received PIP, 6A6, or 6F7 
antibody. 2 d after transfer, we found similar numbers of 
CFSE+ cells in mice that received either PIP or 6A6 antibody 
(Fig. S1 d, left) and no significant differences between numbers 
of CD19+, CD4+, or CD8+ lymphocytes (Fig. S1 d, right). 
Treatment with 6F7 caused a significant depletion of CFSE+ 
lymphocytes, particularly from the CD19+ cell population 
(Fig. S1 d). Furthermore, surface­bound 6A6 was detectable on 
live donor­derived cells in vivo up to 7 d after transfer (Fig. S1 e). 
In addition, 6A6 treatment was unable to prevent GVHD 
caused when BTLA/ donors were used as a source of BM 
for aHSCT (Fig. S1 f). Thus, 6A6 does not deplete lympho­
cytes (Hurchla et al., 2007; Lepenies et al., 2007) but requires 
the expression of BTLA on donor cells to prevent GVHD.
Next, we asked if 6A6 could reverse established GVHD. 
We compared immediate with delayed administration of 
6A6 (Fig. 1 c). Again, immediate 6A6 administration pre­
vented GVHD. In contrast, there was no statistical difference in 
weight loss or clinical scores between mice that received 6A6 
14 d after aHSCT and with mice that received PIP (Fig. 1 c).
6A6 binds to a region of BTLA that is involved in inter­
actions with HVEM (Hurchla et al., 2005). Thus, 6A6 might 
prevent GVHD by preventing HVEM and BTLA interac­
tions, thus blocking costimulatory signaling to donor cells 
(Xu et al., 2007). Although our data indicated that host 
BTLA is not involved (Fig. S1 a), we wished to test this pos­
sibility  independently.  Transfer  of  HVEM/  donor  cells 
caused induction of GVHD when administered with PIP 
(Fig. 1 d). The severity of GVHD caused by HVEM/  
donor cells was somewhat less than that caused by WT donor 
cells (Fig. 1 b), consistent with a study which found that 
HVEM and LIGHT are costimulatory in promoting GVHD 
(Xu  et  al.,  2007).  However,  6A6  also  prevented  GVHD 
caused by HVEM/ donor cells (Fig. 1 d). These results in­
dicate that 6A6 prevents GVHD in a manner that is indepen­
dent of HVEM, suggesting it acts directly through BTLA.
Because the parent­into­irradiated F1 model of aHSCT 
does not result in lethal GVHD, we wished to test the potency 
of the anti­BTLA treatment in a model of complete MHC 
mismatch (H­2b into H­2d) that results in lethal GVHD in un­
treated mice (Lu et al., 2001; Edinger et al., 2003b). Control 
mice developed severe GVHD with pronounced weight loss 
and clinical scores of >6 (Fig. 1 e, left and middle) and died 2554 Anti-BTLA prevents graft-versus-host disease | Albring et al.
mice as donors, using purified GFP­negative cells 
from Foxp3gfp mice to remove preexisting T reg 
cells from the donor population. In this mixed 
aHSCT  setting,  6A6  treatment  similarly  de­
creased the accumulation of T eff cells in both 
populations, but T reg cells expanded only from 
preexisting T reg cells (Fig. 2, f and g; and Fig. S2, 
e and f). Therefore, the donor T reg/T eff cell 
ratio  increased  only  among  the  WT  donor   
T cells and not in the Foxp3gfp donor T cells, as 
assessed by intracellular staining for endogenous 
Foxp3 (Fig. 2 f and Fig. S2 g). In addition, donor­
derived CD4+ T cells, which were originally   
isolated from B6.Foxp3gfp mice as negative for 
GFP expression, remained negative for Foxp3 as 
assessed by the Foxp3­GFP reporter (Fig. S2 e, right).
To further characterize the conditions necessary for the 
expansion of T reg cells, we evaluated what effects anti­
BTLA treatment had on T reg cells in the steady state and 
whether the presence of alloantigen or HVEM on host tissue 
is required. When unmanipulated B6.Foxp3gfp mice received 
6A6, the frequency of T eff cells, T reg cells, or the resulting 
ratio did not change (Fig. S3, a–d). Similarly, although syn­
geneic aHSCT of CB6F1 resulted in a small decrease of T eff 
cells 7 d after transplant, no major accumulation of T reg cells 
and no increased T reg/T eff cell ratio was observed (Fig. S3, 
e–h).  When  HVEM/  donors  and  MHC­mismatched 
HVEM/ recipients were used, the ratio of T reg/T eff  
cells increased by inhibiting the accumulation of T eff cells 
allows the accumulation of T reg cells, resulting in an in­
creased T reg/T eff cell ratio (P > 0.0028; Fig. 2 d). This re­
sult is in agreement with the demonstration that T reg cells 
maintain low levels of BTLA after activation, in contrast to 
conventional  T  cells  which  up­regulate  BTLA  expression 
upon activation (Fig. S2 c; Hurchla et al., 2005). Thus, 6A6 
treatment increases the numbers and the frequency of donor­
derived T reg cells after aHSCT.
6A6 treatment could increase T reg cell frequency either by 
inducing Foxp3 expression in naive donor CD4+ T cells (Chen 
et al., 2003) or by causing in vivo expansion of preexisting   
donor T reg cells relative to T eff cells. To distinguish these alter­
natives, we used B6.Foxp3gfp reporter mice (Fontenot et al., 
2005). We performed mixed aHSCT with WT and Foxp3gfp 
Figure 2.  Anti-BTLA treatment allows for the ex-
pansion of preexisting donor-derived T reg cells by 
inhibiting T eff cell proliferation. (a–e) Lethally irradi-
ated CB6F1 mice received a CFSE-labeled graft from B6.SJL 
donors and were treated with control antibody PIP (open 
circles), 6A6 (closed circles), or 6F7 (closed squares; n = 3 
per group). The number of CD8+ T cells (a), CD4+Foxp3 (b), 
and CD4+ Foxp3+ (c) was calculated from absolute num-
bers of live splenocytes, and the percentage of the lym-
phocyte population was assayed by flow cytometry. (d) The 
ratio of total CD4+Foxp3+/CD4+Foxp3 cells was calculated 
at the indicated time points by dividing the number  
of T reg cells in c by the number of T eff cells in b. (e) CFSE 
intensity of CD8+, CD4+Foxp3, and CD4+Foxp3+, 3 d after 
aHSCT with PIP, 6A6, or 6F7 treatment. (f and g) Lethally 
irradiated CB6F1 mice received aHSCT from B6.SJL mice 
along with purified CD4+ Foxp3-negative T cells from  
B6.Foxp3gfp mice with control antibody (PIP) or 6A6  
(n = 5 per group). After 7 d, splenocytes were assayed by 
flow cytometry to determine the relative frequency of 
CD4+Foxp3+ cells among CD4+ cells (f) or the absolute 
number of CD4+Foxp3+ T reg cells (g). Statistical compari-
sons in a–d are between the PIP- and 6A6-treated groups 
at the indicated time point, and the data are displayed as 
mean ± SEM. Shown are representative data from two 
independent experiments with three to five mice per 
group. P-values of >0.05 are considered not significant  
(n.s). *, 0.01 < P < 0.05; **, 0.001 < P < 0.01.JEM VOL. 207, November 22, 2010  2555
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CD4+BTLA/ population did not change in the presence of 
6A6 (7.9 ± 2 vs. 7.3 ± 2%; Fig. 3, a and c), whereas the T reg 
cell frequency within the CD4+ WT population increased 
more than threefold in the presence of 6A6 (48 ± 10 vs. 14.4 ± 
5.5%; Fig. 3, a and b).
Importantly, 6A6 treatment decreased T eff cell numbers 
more than fivefold from 2.6 × 105 ± 4.6 × 104 cells in the 
control group to 3.9 × 104 ± 1.4 × 104 (P < 0.0001; Fig. 3 d), 
indicating that WT­BTLA+/+ T eff cells are the main target 
of the anti­BTLA treatment. WT and BTLA/ T reg cells 
(Fig. S3, i–l) as observed before (Fig. 2, d and g). Collec­
tively, these results suggest that 6A6 has no effect in the steady 
state, does not involve HVEM, and requires allostimulation 
to increase the T reg/T eff cell ratio.
Because BTLA is expressed on both T eff and T reg cells, 
we tested whether the increased T reg/T eff cell ratio was the 
result of a decrease in T eff cell expansion, an increased pro­
liferation of T reg cells, or both by performing a mixed   
aHSCT using congenically marked WT BTLA+/+ and BTLA/ 
donors. In this setting, the frequency of T reg cell within the 
Figure 3.  Direct engagement of BTLA on T eff cells leads to an increased frequency of CD4+Foxp3+ cells. Lethally irradiated CB6F1 mice re-
ceived a 1:1 mixed aHSCT with WT-B6.SJL and B6 BTLA/ donor cells (a–e) with either control antibody (PIP) or 6A6 (n = 5 per group). After 7 d, spleno-
cytes were analyzed by flow cytometry. (a) Shown are FACS plots to identify donor cells as H-2Kd and CD4+ (left). Intracellular Foxp3 was detected 
among CD4+ T cells (right) gated on WT-B6.SJL (CD4+CD45.1+ H-2Kd) or B6 BTLA+/+ (CD4+CD45.1 H-2Kd) donor cell populations as indicated. Numbers 
represent the percentage of cells within the indicated gates. The ratios of the number of WT T reg/WT T eff cells (b) and KO T reg/ KO T eff cells (c) are 
shown, as well as the total number of T eff cells (d) and T reg cells (e) from the indicated donors after treatment with control antibody (PIP, open bars) or 
6A6 (closed bars). (f and g) Lethally irradiated BALB/c mice received a 1:1 mixture of purified WT-B6.SJL and BTLA/ CD4+ cells and T reg cells from B6.
Foxp3gfp mice, with either control antibody PIP or 6A6 (n = 3–4 per group). After 7 d, splenocytes were analyzed by flow cytometry to determine the ratio 
of WT T reg/WT T eff cells (f) or WT T reg/BTLA/ T eff cells (g). Data are displayed as mean ± SEM. Shown are representative data from two independent 
experiments. (h–j) Recipient BALB/c mice received TCD-BM and splenocytes from T reg cell ablated or unmanipulated Foxp3DTR mice and PIP or 6A6 as 
indicated. Survival curves (h), weight curves (i), and clinical scores (j) are shown for 6A6-treated mice that received a graft from either untreated (no DT) 
Foxp3DTR donors (dashed line or filled squares; n = 5) or a graft from DT-treated (T reg depl.) Foxp3DTR donors (solid line or filled circles; n = 5) and PIP-
treated mice that received a graft from DT-treated or untreated (T reg depl. and no DT) Foxp3DTR donors (dotted line or open circles; n = 10). Data are 
shown as mean ± SD from two independent experiments. P-values of >0.05 are considered not significant (n.s). **, 0.001 < P < 0.01; ***, P < 0.001.2556 Anti-BTLA prevents graft-versus-host disease | Albring et al.
T reg/BTLA/ T eff cell ratio even decreased (Fig. 3 g and 
Fig. S4 i), suggesting that low expression levels of BTLA on 
T  reg  cells  inhibits  their  expansion  when  proliferation  of 
BTLA/ T eff cells is not restricted.
To ask whether the inhibition of T eff cells had an effect 
on GVHD in the absence of T reg cells, we used C57BL/6 
Foxp3DTR mice as donors in the lethal model of GVHD. Pre­
treatment with diphtheria toxin reduced T reg cells by >95% 
in Foxp3DTR donors. 90% of control animals died within 14 d 
of aHSCT, irrespective of whether or not the BM graft con­
tained T reg cells (Fig. 3 h). All mice that were treated with the 
6A6 antibody survived beyond day 70 (Fig. 3 h). Mice that re­
ceived a graft with T reg cells and 6A6 eventually recovered   
to 90% of their starting weight (Fig. 3 i) and developed 
do not expand significantly in the presence of BTLA/ T eff 
cells (Fig. 3 e), confirming our observation that T reg cells 
expand only when T eff cells express BTLA and are inhibited 
by 6A6. To exclude any indirect effects on host tissues, we 
cotransferred purified populations of WT T reg cells together 
with WT or BTLA/ T eff cells into BALB/c recipients, 
which express an allele of BTLA not recognized by 6A6 (Fig. 3, 
f and g; and Fig. S4; Hurchla et al., 2005). The WT T reg/
WT T eff cell ratio increased after 6A6 treatement (P < 0.0004; 
Fig. 3 f) as observed before (Fig. 2 g and Fig. 3 b). In contrast, 
when BTLA/ T eff cells were present the WT T reg/
BTLA/ T eff cell ratio did not increase (Fig. 3 g), indicat­
ing that the expansion of T reg cells is caused by 6A6 reduc­
ing the expansion of T eff cells. In this setting, the WT   
Figure 4.  Anti-BTLA treatment does not lead to global immunosuppression. (a) Representative images of A20-Luc tumor cell localization 7 d (left) 
and 15 d (right) after aHSCT in lethally irradiated BALB/c mice that had received A20-Luc lymphoma cells with TCD-BM alone (n = 10) or together with 
splenocytes from C57BL/6 mice and control antibody PIP (n = 10) or 6A6 (n = 10). (b) Shown are units of photons per second for individual animals from 
panel a for days 5 (n = 5), 7 (n = 5), and 15 (n = 10) after aHSCT, as well as unmanipulated BALB/c mice (day 0, n = 12) for comparison. Asterisks indicate 
statistically significant differences between TCD-BM and 6A6 groups. Shown are cumulative data from two independent experiments, with each point 
representing the BLI signal from an individual mouse. Horizontal lines represent the mean BLI signal. Vertical lines serve to separate experimental groups. 
(c) Survival data of mice from a and from mice that received TCD-BM alone without tumor for comparison. Shown are cumulative data from two inde-
pendent experiments. (d) CB6F1 BMC and splenocytes from syngeneic (green line; n = 10) or C57BL/6 donors and antibodies PIP (red line; n = 10) or 6A6 
(blue line; n = 10) were infected with MCMV 4 wk after aHSCT and were monitored for survival. PIP-treated uninfected mice (orange line, n = 10) served 
as controls. Shown are cumulative data from two independent experiments. Data are shown as mean ± SD from two independent experiments. P-values 
of >0.05 are considered not significant (n.s). **, 0.001 < P < 0.01; ***, P < 0.001.JEM VOL. 207, November 22, 2010  2557
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cells and allowing the relative expansion of naturally occur­
ring T reg cells. Once established, this new balance of T eff 
cells  is  sufficient  to  prevent  GVHD  permanently  while   
allowing for intact responses to viral and bacterial pathogens, 
as well as GVT effects. Thus, BTLA may represent a novel 
therapeutic target in prevention of human GVHD. Increas­
ing the safety of aHSCT could potentially allow its appli­
cation more widely as a tolerogenic therapy in treatment of 
autoimmune disorders or solid organ transplantation, for which 
it is currently performed only experimentally (Sykes and Nikolic, 
2005; Kawai et al., 2008).
MATERIALS AND METHODS
Mice  and  BM  transplantation.  B6.SJL­Ptprca  Pep3b/BoyJ  (B6.SJL), 
C57BL/6, and C57BL/6 × BALB/c F1 (CB6F1) mice were obtained from The 
Jackson Laboratory or bred in our facility. BTLA/ (Watanabe et al., 2003), 
Hvem/ (Wang et al., 2005), Foxp3gfp (Fontenot et al., 2005), and Foxp3DTR 
(Kim et al., 2007) mice were backcrossed to C57BL/6 for at least nine genera­
tions. HVEM/ H2­Kb/d or H2­Kd/d were obtained by crossing HVEM/ 
mice on a B6 (H2­Kb/b) background to BALB/c (H2­Kd/d) mice. The resulting 
HVEM+/  H2­Kd/b  F1  mice  were  intercrossed  to  obtain  HVEM/  
H2­Kb/d or H2­Kd/d F2 recipients. Mice were 12–18 wk old and sex matched 
for all experiments. Mice were bred and maintained in our specific pathogen–
free animal facility according to institutional guidelines with protocols approved 
by the Animal Studies Committee of Washington University.
Cell transplantation and assessment of GVHD. Mice received trans­
plants according to a standard protocol as previously described (Stelljes et al., 
2008). In brief, BMCs were harvested by flushing tibia and femurs of donor 
mice. For the nonlethal parent­into­F1 model of GVHD, CB6F1 (H­2b/d) 
recipients were lethally irradiated with 9 Gy total body irradiation using a 
137Cs source at a dose rate of 70 cGy/min and reconstituted with 2 × 107 
BMCs and 107 splenocytes from syngeneic (H­2b/d) or parental C57BL/6 
donors (H­2b). For the lethal model of GVHD, BALB/c (H­2d) recipients 
were lethally irradiated with 8 Gy total body irradiation using a 137Cs source 
at a dose rate of 70 cGy/min and reconstituted with 2 × 107 TCD­BM 
alone or an additional 107 splenocytes from allogeneic C57BL/6 donors (H­2b). 
To obtain TCD­BM, cells were depleted of CD4+ and CD8+ cells by mag­
netic depletion (Miltenyi Biotec) according to the manufacturer’s recom­
mendation. In experiments where a T reg cell–depleted graft from Foxp3DTR 
donors was used, recipients received an intraperitoneal injection of 20 µg 
diphtheria toxin on the day of BMT. GVHD was monitored by calculating 
the loss in total body weight. Body weights were measured before transplan­
tation and three times a week after transplantation. Clinical GVHD intensity 
was scored by assessing weight loss, posture, activity, fur texture, and skin 
integrity (Cooke et al., 1996). Histopathologic analyses of the bowel were 
performed on hematoxylin and eosin–stained tissue.
Administration of antibody. In some experiments, mice received at the time 
of aHSCT, unless otherwise noted, a single intraperitoneal injection of   
10–20 µg/g body weight of anti­BTLA antibodies 6A6 and 6F7, whose proper­
ties we have previously published in detail (Hurchla et al., 2005). In brief, the 
IgG hamster monoclonal antibody 6A6 is specific for the C57BL/6 allele of 
BTLA and does not deplete BTLA­expressing cells in vivo (Hurchla et al., 2007; 
Lepenies et al., 2007). The IgG1 mouse monoclonal anti­BTLA antibody 6F7 
recognizes all known alleles of BTLA (Hurchla et al., 2005) and has been shown 
to deplete BTLA­expressing cells in vivo. The IgG1 hamster monoclonal anti­
GST antibody PIP (Gronowski et al., 1999) was used as an isotype control.
Cell purification and depletion. To obtain purified populations of CD4+ 
Foxp3gfp­negative cells or CD4+ Foxp3gfp­positive cells in the indicated ex­
periments, Foxp3gfp splenocytes were stained with CD4+ and the desired 
population was purified by cell sorting on the MoFlo cytometer (Dako). 
low­grade GVHD with scores ranging from 1 to 3, as seen be­
fore (Fig. 1 e). Mice that received a T reg cell–depleted graft 
and 6A6, however, recovered only 70–80% of their starting 
weight and had more severe GVHD scores ranging from 3 to 5 
(Fig. 3 j). These data highlight that forced inhibition of T eff 
cells through BTLA (Fig. 3 d) is sufficient to prevent lethality. 
Nonetheless, the relative expansion of T reg cells (Fig. 3, b and f) 
bears biological significance, as they are required to protect the 
host from clinical GVHD (Fig. 3, i and j).
Because engagement of BTLA by 6A6 inhibited T eff cell 
proliferation, we wondered whether this treatment allowed for 
antigen­specific responses to tumors and pathogens. First, we 
examined whether graft­versus­tumor (GVT) activity was 
maintained after 6A6 treatment (Fig. 4, a–c). We used a model 
of minimal residual disease after aHSCT that utilizes biolumi­
nescence imaging (BLI) of luciferase­expressing A20­Luc leu­
kemia cells (H­2d) in vivo (Edinger et al., 2003a). In this model, 
GVT activity requires cytolytic activity of T cells to control the 
tumor (Edinger et al., 2003b). Transplantation of A20­Luc leu­
kemia cells with TCD­BM alone resulted in progressive tumor 
growth (Fig. 4, a and b). In mice that had received a T cell–
containing graft with or without the 6A6 antibody, however, 
tumor was never detectable by BLI, suggesting that GVT ef­
fects were intact. Although all control mice died before day 45 
of severe GVHD, 90% of 6A6­treated mice survived beyond 
day 90 (Fig. 4 c). To exclude any antibody­mediated anti­ 
tumor effects, we confirmed that the 6A6 antibody does not 
bind to A20 cells, which was expected because of their BALB/c 
origin (Fig. S2 d). To document initial tumor engraftment, we 
quantified the total tumor number A20­GFP cells in the BM by 
flow cytometry 7 d after aHSCT (Fig. S3 m).
We next examined immune responses to murine CMV 
(MCMV; Nguyen et al., 2008) 4 wk after aHSCT. All ani­
mals that had undergone syngeneic aHSCT survived for >60 d 
after infection (Fig. 4 d). Of the mice in the allogeneic group 
that had received the PIP antibody, 70% died within 10 d of 
infection compared with 20% of the 6A6­treated mice. Thus, 
although 6A6 treatment prevents GVHD, it allows for resis­
tance to MCMV, unlike PIP­treated control recipients.
To test the immune response against bacterial infection, 
animals were infected with the intracellular bacterium Listeria 
monocytogenes. 3 d after infection, animals that had received 
the PIP antibody had either higher (P = 0.0005 for liver and 
P = 0.1816 for spleen) or lower L. monocytogenes organ bur­
dens (P = 0.0227 for liver and P = 0.0059 for spleen; Fig. S3, 
n–p), as has been described previously (Miura et al., 2000).   
In  contrast,  anti­BTLA–treated  mice  controlled  infection 
similarly to both control groups, indicating an intact innate 
immune response (Fig. S3, n–p). These preliminary results 
suggest that 6A6­treated mice were similarly resistant to   
L. monocytogenes infection to unmanipulated mice.
In summary, this study demonstrates that the anti­BTLA 
antibody 6A6 administered at the time of aHSCT prevents 
GVHD without the need for additional immunosuppressive 
therapy. The mechanism of action is through direct engage­
ment of BTLA on donor T cells, selectively inhibiting T eff 2558 Anti-BTLA prevents graft-versus-host disease | Albring et al.
(Sigma­Aldrich) and 5 µg/ml LPS and spun at 930 rcf for 1 h before being cul­
tured at 37°C for 24 h. 72 h after infection, cells were sorted for high GFP ex­
pression on a FACSAria II (BD) and stable GFP expression of >95% was 
confirmed several times by flow cytometry at later time points.
Models of infectious disease. For MCMV infection, mice were infected 
with Smith strain MCMV 4 wk after aHSCT. Virus preparation and admin­
istration was performed as described previously (Krug et al., 2004). In brief, 
a salivary gland stock of MCMV was prepared from BALB/c mice, with a 
titer of 6.75 × 106 PFU/ml. Mice were infected intraperitoneally with a low 
dose  of  virus  (104  PFU/mouse)  and  then  monitored  for  survival.  For   
L. monocytogenes infection, mice were infected intravenously with 2.5 × 104 
L. monocytogenes (strain EGD; gift from E.R. Unanue, Washington Univer­
sity School of Medicine, St. Louis, MO) 3 mo after aHSCT. To determine 
organ L. monocytogenes burden at day 3 after infection, spleens and livers were 
homogenized in PBS plus 0.05% Triton X­100. Serial dilutions of homoge­
nate were plated on brain heart infusion agar, and bacterial CFUs were as­
sessed after overnight growth at 37°C. Small portions of spleen and liver 
were also fixed in 10% formalin and stained with hematoxylin and eosin.
Statistical analysis. A Student’s unpaired two­tailed t test with a 95% con­
fidence interval was used for statistical analyses of body weight data, clinical 
scores, and cell numbers. For analyses of survival data the log­rank test was 
used. A Mann­Whitney unpaired two­tailed Student’s t test with a 95% 
confidence interval was used for statistical analyses of bioluminescence data 
in Fig. 4. Statistical analyses were done using Prism 4 (GraphPad Software, 
Inc.). FACS data are expressed as means ± SEM. All other data are presented 
as means ± SD. All experiments have been repeated at least once with three 
to five mice per group, unless stated otherwise.
Online supplemental material. Fig. S1 demonstrates that BTLA expres­
sion by recipient tissue does not promote GVHD and 6A6 antibody does not 
deplete lymphocytes. Fig. S2 shows that 6A6 treatment does not lead to   
donor T eff cell anergy and expands preexisting T reg cells. Fig. S3 shows that 
6A6 inhibition of T eff cells and expansion of T reg cells requires allostimu­
lation but not HVEM expression by donor or host. Fig. S4 shows that 6A6 
alters the T reg cell/effector CD4+ T cell ratio by directly inhibiting BTLA­
expressing T cells. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20102017/DC1.
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